Amneal, BIAL ink U.S. licensing agreement for Ongentys
Ongentys (opicapone) is an adjunctive therapy for the treatment of Parkinson’s disease.
Source: drugstorenews.com
📰 Max Bricchi News
Max Bricchi News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Max Bricchi. Real-time updates on events, politics, business and more.
Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)
ONGENTYS® (opicapone) is a leading adjunctive therapy for the treatment of Parkinson’s DiseaseComplements Amneal’s existing Parkinson’s franchise and further expands specialty portfolioBRIDGEWATER, N.J. & PORTO, Portugal--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) and BIAL - Portela &...
Source: pharmiweb.com